Takeda Globally Signs Licensing- Co-Development & Co-Promotion Agreement with Enterome for its EB8018 Candidate
Shots:
- Enterome to get $50M upfront plus $640M as milestones payments and future equity investment commitment from Takeda. The companies will jointly co-develop EB8018 and if approved- the product will be co-promoted in the US with equal profit/cost sharing
- Takeda to get hold of exclusive license rights for EB8018 to commercialize outside the US and give royalties on sales to Enterome
- EB8018 PO is a novel P-Ib candidate indicated in Crohn’s disease- testing its safety- tolerability- PK & efficacy and has successfully completed its P-Ia
Ref: Enterome Biosciences | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com